
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Bivalent mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Bivalent mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LVRNA021
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LVRNA021 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : LVRNA021
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19
Details : LVRNA009 is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Variant mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
Details : SARS-CoV-2 Variant mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : SARS-CoV-2 Variant mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 Per H Share
Details : The net proceeds will be used for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline including LVRNA009, funding the capital expenditure on the construction of new production facilities for new vaccine products.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : COVID-19 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COVID-19 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : COVID-19 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
